期刊文献+

Clusterin、bcl-2及FasL在前列腺癌中的表达及相关性研究 被引量:1

Expression and significance of Clusterin ,bcl-2 and FasL in prostate cancer
暂未订购
导出
摘要 目的:通过检测新的凋亡抑制因子Clusterin在前列腺癌组织中的表达,探讨其与前列腺癌发生发展的关系及其与bcl-2和FasL表达的关系。方法:A采用免疫组织化学染色法检测Clusterin、bcl-2、FasL在10例正常前列腺组织、15例良性前列腺增生组织(BPH)、49例前列腺癌组织标本中的表达。结果:Clusterin在前列腺正常、增生、癌组织中的阳性及弱阳性表达率分别为10%(1/10)、66.6%(10/15)、91.8%(45/49)。前列腺癌组织中Clusterin表达水平明显高于前列腺正常组织(P<0.005)及增生组织(P<0.005),且在癌组织中与肿瘤临床分期(P<0.001)、病理分级(P<0.001)呈正相关。比较Clusterin与bcl-2在前列腺癌组织中的表达,差异有显著性(P<0.05)。比较Clusterin与FasL在前列腺癌组织中的表达,差异也有显著性(P<0.05)。结论:Clusterin基因可能通过抑制凋亡在前列腺癌的发生发展中发挥重要作用,且其表达与bcl-2、FasL的异常表达密切相关。 Objective:To investigate the expression and significance of an inhibitor gene of apoptosis,Clusterin,in prostate cancer,and its relationship with the expression of bcl-2,FasL.Methods:The expression of Clusterin,bcl-2 and FasL in sample of 10 normal prostate,15 BPH and 49 prostate cancer were examined by immunohistochemical stain.Results:The rate of positive or weak positive for normal prostate,BPH and prostate cancer was 10%(1/10),66.6%(10/15)and 91.8%(45/49) respectively.The expression level of Clusterin in prostate cancer was much higher than in normal prostate(P<0.005),BPH(P<0.005),and it was related positively with clinical stage(P<0.001)and pathological grade(P<0.001)of prostate cancer.Clusterin positive cases were strongly associated with bcl-2 expression(P<0.05)and FasL expression(P<0.05).Conclusion:Clusterin,alone or in cooperarion with bcl-2 and FasL,may play an important role in the onset and progression of prostate cancer by the antiapoptosis pathway.
作者 陈刚 唐伟
出处 《重庆医科大学学报》 CAS CSCD 2005年第3期409-411,420,共4页 Journal of Chongqing Medical University
关键词 前列腺肿瘤 凋亡 CLUSTERIN FASL BCL-2 免疫组织化学 Prostatic neoplasms Apoptosis Clusterin FasL bcl-2 Immunohistochemistry
  • 相关文献

参考文献9

  • 1Sintich SM, Steinberg J, Kozlowski JM, et al. Cytotoxic sensitivity to tumor necrosis factor - alpha in Pc3 and LNCaP prostatic cancer cells is regulated by extracellular levels of SGP - 2 (clusterin)[ J ]. Prostate, 1999, 39 (2) : 87 — 93.
  • 2Kirszbaum L, Sharpe JA, Murphy B, et al. Molecular cloning and characterization of the novel human complement - associated protein, SP - 40,40 : a link between the complement and reproductive system[ J ]. EMBO J, 1989, 8 : 711 — 718.
  • 3Steinberg I,Oyasu R,Lang S, et al. Intracellular levels of SGP- 2(Clusterin)correlate with tumor grade in prostate cance r[ J ]. Clin Cancer Res, 1997, 3 (10) : 1707 — 1711.
  • 4张徽,刘纯,李圆圆.47例甲状腺癌中FasL检测的病理学意义[J].重庆医科大学学报,2003,28(1):69-71. 被引量:2
  • 5Mapara,MY,Bargou R,Zugck C,et al. APO - 1 mediated apoptosis or proliferation in human chronic B lymphocytic leukemia, correlation with bcl - 2 oncogene expression[ J ]. Eur J Immunol, 1993, 23 (3) : 702 — 708.
  • 6Mikata K, Uemura H, Ohuchi H, et al. Inhibition of growth of human prostate cancer xenograft by transfection of P53 gene: gene transfer by electroporation [ J ]. Mol Cancer Ther, 2002, 1 (4) : 247 — 252.
  • 7Gleave M, Tolcher A, Miyake H, et al. Progression to androgen independence is delayed by adjuvant treatment with anti-sene bcl - 2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model[ J ]. Clin Cancer Res, 1999, 5(10) : 2891 — 2898.
  • 8Miyake H, Nelson C, Rermie PS, et al. Testosterone - repressed prostate message - 2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer [ J ].Cancer Res, 2000 ,60( 1 ) : 170 — 176.
  • 9Gleave ME, Miyake H, Zellweger T, et al. Use of anti-sense oligonucleotides targeting the antiapoptotic gene, Clus-terin/testosterone - repressed prostate message2 to enhance androgen sensitivity and chemosensitivity in prostate cancer[ J ].Urology,2001,58(2 suppl 1) : 39 — 49.

二级参考文献8

  • 1[1]Griffith TS, Brunner T, Fletcher SM, et al. Fas Ligand induced apoptosis as a mechanism of immune privilege[ J ]. Science, 1995; 270 (5239): 1189 - 1192.
  • 2[2]Kagi D, Vignaux F, Ledermann B, et al. Fas and perforin pathways as major mechanisms of T cell - mediated cytotoxicity[J]. Science, 1994;265(5171) :528 - 530.
  • 3[3]O'Connell J,O'Sullivan GC, Collins, et al. The Fas coun terattack: Fas mediated T cell killing by colon cancer cells expressing Fas Ligand [ J ]. J Exp Med, 1996; 184 ( 3 ): 1075-1082.
  • 4[4]Mitsiades N, Poulaki V, Kotoula V, et al. Fas ligand ispresent in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase [ J ]. Am J Pathol,1998; 153(6) :1947 - 1956.
  • 5[5]Mullauer L, Mosberger I, Chott A, et al. Fas ligand ex pression in nodal nonHodgkin' s lymphoma [ J ]. Med Pathol,1998;11(4) :369 - 375.
  • 6[6]Mitsiades N, Poulaki V, Mastorakos G, et al. Fas ligand expression in thyroid carcinoma: A potential mechanism of im mune evasion [ J ]. Endocrinol Metab, 1999; 84 ( 8 ): 2924 -2932.
  • 7[7]Tanimoto C, Hirakawa S, Kawasaki H, et al. Apoptosis in thyroid disease: a histochemical study [J]. Endocr J, 1995; 42 (2): 193 - 201.
  • 8[8]Basolo F, Pollina L, Fontanini G, et al. Apoptosis and pro liferation in thyroid carcinoma correlation with BcL - 2 and P53protein expression[J ]. Br J Cancer, 1997; 75 (4): 537 - 541.

共引文献1

同被引文献5

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部